SOPs for CMD animal models
Standard protocols
Cure CMD and TREAT-NMD are collaborating in establishing standard protocols for efficacy studies in the laminin deficient mouse model LAMA2dy-W, the best described mouse model for a CMD disease, and with the aid of AFM funding, also for additional CMD animal models.
With the involvement of several dedicated CMD researchers, readout parameters were selected that are appropriate to show the efficacy of a new potential drug, and that are related to patient outcomes. For each of these parameters, small groups of experts will develop a standard assessment protocol.
The availability of standard protocols will implement research and increase the comparability of results.
The SOPs that have already been completed can be downloaded from this site and others will be added in the future. The last date each SOP was reviewed can be found under the code on the left of the page.
Contact
Anne Rutkowski
Dr Anne Rutkowski is a practising board-certified emergency medicine physician in Los Angeles. Anne’ …
Recommendations on the care and handling of the MDC1A mouse model dyW
Janice Dominov – 25 June 2019
Assessment of peripheral nerve pathology in laminin-alpha-2-deficient mice
Jeffrey B. Miller – 17 May 2019
Use of Grip Strength Meter to Assess the Limb Strength of dyw Mice
Anne Connolly – 12 July 2017
Gait assessment in a canine model of XLMTM using an instrumented carpet
Melissa Goddard – 10 July 2017
Respiratory assessment of a canine model of XLMTM using non-invasive respiratory impedence plethysmography
Melissa Goddard – 10 July 2017
Neuromuscular junction imaging on whole muscles and muscle sections in CMD animal models
Gregorius Valdez – 26 July 2016
Histopathology in Hematoxylin & Eosin stained muscle sections
Markus A. Ruegg – 28 January 2016
Single muscle contractile measurements in vivo and in situ
Rich Lovering – 23 May 2015
Histopathology in Masson Trichrome stained muscle sections
Markus A. Ruegg – 28 January 2014
Disclaimer: TREAT-NMD and the authors of the SOPs disclaim, without limitation, all liability for any loss or damage of any kind, including any direct, indirect or consequential damages, which might be incurred in connection with the information and procedures contained in these SOPs.
